Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 214 entries
Sorted by: Best Match Show Resources per page
Brain natriuretic peptide elevation and the development of atrial fibrillation following coronary artery bypass surgery.

Interactive cardiovascular and thoracic surgery

Cosgrave J, Foley JB, McGovern E, Bennett K, Young V, Tolan M, Crean P, Walsh M.
PMID: 17670529
Interact Cardiovasc Thorac Surg. 2006 Apr;5(2):111-4. doi: 10.1510/icvts.2005.118265. Epub 2006 Jan 10.

The study was designed to determine whether the development of atrial fibrillation is associated with post-operative left ventricular dysfunction and subsequent left atrial stretch. We recruited 133 patients with well preserved pre-operative left ventricular function undergoing bypass surgery. Brain...

Cite
Cosgrave J, Foley JB, McGovern E, et al. Brain natriuretic peptide elevation and the development of atrial fibrillation following coronary artery bypass surgery. Interact Cardiovasc Thorac Surg. 2006;5(2):111-4doi: 10.1510/icvts.2005.118265.
Cosgrave, J., Foley, J. B., McGovern, E., Bennett, K., Young, V., Tolan, M., Crean, P., & Walsh, M. (2006). Brain natriuretic peptide elevation and the development of atrial fibrillation following coronary artery bypass surgery. Interactive cardiovascular and thoracic surgery, 5(2), 111-4. https://doi.org/10.1510/icvts.2005.118265
Cosgrave, John, et al. "Brain natriuretic peptide elevation and the development of atrial fibrillation following coronary artery bypass surgery." Interactive cardiovascular and thoracic surgery vol. 5,2 (2006): 111-4. doi: https://doi.org/10.1510/icvts.2005.118265
Cosgrave J, Foley JB, McGovern E, Bennett K, Young V, Tolan M, Crean P, Walsh M. Brain natriuretic peptide elevation and the development of atrial fibrillation following coronary artery bypass surgery. Interact Cardiovasc Thorac Surg. 2006 Apr;5(2):111-4. doi: 10.1510/icvts.2005.118265. Epub 2006 Jan 10. PMID: 17670529.
Copy Download .nbib Format: NLM
Morbidity and mortality characteristics of Asian strain influenza.

Public health reports (Washington, D.C. : 1896)

Chin TD, Foley JF, Doto IL, Gravelle CR, Weston J.
PMID: 19316351
Public Health Rep. 1960 Feb;75(2):149-158.

No abstract available.

Cite
Chin TD, Foley JF, Doto IL, et al. Morbidity and mortality characteristics of Asian strain influenza. Public Health Rep. 1960;75(2):149-158
Chin, T. D., Foley, J. F., Doto, I. L., Gravelle, C. R., & Weston, J. (1960). Morbidity and mortality characteristics of Asian strain influenza. Public health reports (Washington, D.C. : 1896), 75(2), 149-158.
Chin, Tom D Y, et al. "Morbidity and mortality characteristics of Asian strain influenza." Public health reports (Washington, D.C. : 1896) vol. 75,2 (1960): 149-158.
Chin TD, Foley JF, Doto IL, Gravelle CR, Weston J. Morbidity and mortality characteristics of Asian strain influenza. Public Health Rep. 1960 Feb;75(2):149-158. PMID: 19316351; PMCID: PMC1929395.
Copy Download .nbib Format: NLM
Genetic diversity of Borrelia burgdorferi sensu lato isolates from Northeastern China.

Vector borne and zoonotic diseases (Larchmont, N.Y.)

Chu CY, Jiang BG, He J, Gao Y, Zhang PH, Wu XM, Zhang WY, Shi H, Gaowa HS, Wang JB, Foley JE, Liu W, Cao WC.
PMID: 21142958
Vector Borne Zoonotic Dis. 2010 Dec 13; doi: 10.1089/vbz.2009.0195. Epub 2010 Dec 13.

Thirty-two strains of Borrelia burgdorferi sensu lato were isolated from Ixodes persulcatus ticks collected from northeastern China from May to June in 2004 and 2005. Restriction fragment length polymorphism (RFLP) analysis and sequence analysis of 5S-23S rRNA intergenic spacer...

Cite
Chu CY, Jiang BG, He J, et al. Genetic diversity of Borrelia burgdorferi sensu lato isolates from Northeastern China. Vector Borne Zoonotic Dis. 2010;doi: 10.1089/vbz.2009.0195.
Chu, C. Y., Jiang, B. G., He, J., Gao, Y., Zhang, P. H., Wu, X. M., Zhang, W. Y., Shi, H., Gaowa, H. S., Wang, J. B., Foley, J. E., Liu, W., & Cao, W. C. (2010). Genetic diversity of Borrelia burgdorferi sensu lato isolates from Northeastern China. Vector borne and zoonotic diseases (Larchmont, N.Y.), . https://doi.org/10.1089/vbz.2009.0195
Chu, Chen-Yi, et al. "Genetic diversity of Borrelia burgdorferi sensu lato isolates from Northeastern China." Vector borne and zoonotic diseases (Larchmont, N.Y.) vol. (2010). doi: https://doi.org/10.1089/vbz.2009.0195
Chu CY, Jiang BG, He J, Gao Y, Zhang PH, Wu XM, Zhang WY, Shi H, Gaowa HS, Wang JB, Foley JE, Liu W, Cao WC. Genetic diversity of Borrelia burgdorferi sensu lato isolates from Northeastern China. Vector Borne Zoonotic Dis. 2010 Dec 13; doi: 10.1089/vbz.2009.0195. Epub 2010 Dec 13. PMID: 21142958.
Copy Download .nbib Format: NLM
THE HISTORY OF CAESAREAN SECTION.

Canadian Medical Association journal

Boley JP.
PMID: 20319891
Can Med Assoc J. 1935 May;32(5):557-9.

No abstract available.

Cite
Boley JP. THE HISTORY OF CAESAREAN SECTION. Can Med Assoc J. 1935;32(5):557-9
Boley, J. P. (1935). THE HISTORY OF CAESAREAN SECTION. Canadian Medical Association journal, 32(5), 557-9.
Boley, J P. "THE HISTORY OF CAESAREAN SECTION." Canadian Medical Association journal vol. 32,5 (1935): 557-9.
Boley JP. THE HISTORY OF CAESAREAN SECTION. Can Med Assoc J. 1935 May;32(5):557-9. PMID: 20319891; PMCID: PMC1561135.
Copy Download .nbib Format: NLM
Diagnosis and treatment of early pulmonary tuberculosis.

Bulletin. Chicago Medical Society

FOLEY EF.
PMID: 15396099
Bull Chic Med Soc. 1949 Dec 17;52(25):489-92.

No abstract available.

Cite
FOLEY EF. Diagnosis and treatment of early pulmonary tuberculosis. Bull Chic Med Soc. 1949;52(25):489-92
FOLEY, E. F. (1949). Diagnosis and treatment of early pulmonary tuberculosis. Bulletin. Chicago Medical Society, 52(25), 489-92.
FOLEY, E F. "Diagnosis and treatment of early pulmonary tuberculosis." Bulletin. Chicago Medical Society vol. 52,25 (1949): 489-92.
FOLEY EF. Diagnosis and treatment of early pulmonary tuberculosis. Bull Chic Med Soc. 1949 Dec 17;52(25):489-92. PMID: 15396099.
Copy Download .nbib Format: NLM
Impact of insulin resistance, body mass index, disease duration, and duration of metformin use on the efficacy of vildagliptin.

Diabetes therapy : research, treatment and education of diabetes and related disorders

Schweizer A, Dejager S, Foley JE.
PMID: 22736406
Diabetes Ther. 2012 Nov;3(1):8. doi: 10.1007/s13300-012-0008-5. Epub 2012 Jun 27.

INTRODUCTION: The optimal stage for dipeptidyl peptidase-4 (DPP-4) inhibitor therapy in the course of type 2 diabetes mellitus (T2DM) is still under discussion, with often a perception that treatment with these agents may be less beneficial with increasing disease...

Cite
Schweizer A, Dejager S, Foley JE. Impact of insulin resistance, body mass index, disease duration, and duration of metformin use on the efficacy of vildagliptin. Diabetes Ther. 2012;3(1):8doi: 10.1007/s13300-012-0008-5.
Schweizer, A., Dejager, S., & Foley, J. E. (2012). Impact of insulin resistance, body mass index, disease duration, and duration of metformin use on the efficacy of vildagliptin. Diabetes therapy : research, treatment and education of diabetes and related disorders, 3(1), 8. https://doi.org/10.1007/s13300-012-0008-5
Schweizer, Anja, et al. "Impact of insulin resistance, body mass index, disease duration, and duration of metformin use on the efficacy of vildagliptin." Diabetes therapy : research, treatment and education of diabetes and related disorders vol. 3,1 (2012): 8. doi: https://doi.org/10.1007/s13300-012-0008-5
Schweizer A, Dejager S, Foley JE. Impact of insulin resistance, body mass index, disease duration, and duration of metformin use on the efficacy of vildagliptin. Diabetes Ther. 2012 Nov;3(1):8. doi: 10.1007/s13300-012-0008-5. Epub 2012 Jun 27. PMID: 22736406; PMCID: PMC3508106.
Copy Download .nbib Format: NLM
Gait analysis of teenagers and young adults diagnosed with autism and severe verbal communication disorders.

Frontiers in integrative neuroscience

Weiss MJ, Moran MF, Parker ME, Foley JT.
PMID: 23730274
Front Integr Neurosci. 2013 May 20;7:33. doi: 10.3389/fnint.2013.00033. eCollection 2013.

Both movement differences and disorders are common within autism spectrum disorders (ASD). These differences have wide and heterogeneous variability among different ages and sub-groups all diagnosed with ASD. Gait was studied in a more homogeneously identified group of nine...

Cite
Weiss MJ, Moran MF, Parker ME, et al. Gait analysis of teenagers and young adults diagnosed with autism and severe verbal communication disorders. Front Integr Neurosci. 2013;7:33doi: 10.3389/fnint.2013.00033.
Weiss, M. J., Moran, M. F., Parker, M. E., & Foley, J. T. (2013). Gait analysis of teenagers and young adults diagnosed with autism and severe verbal communication disorders. Frontiers in integrative neuroscience, 733. https://doi.org/10.3389/fnint.2013.00033
Weiss, Michael J, et al. "Gait analysis of teenagers and young adults diagnosed with autism and severe verbal communication disorders." Frontiers in integrative neuroscience vol. 7 (2013): 33. doi: https://doi.org/10.3389/fnint.2013.00033
Weiss MJ, Moran MF, Parker ME, Foley JT. Gait analysis of teenagers and young adults diagnosed with autism and severe verbal communication disorders. Front Integr Neurosci. 2013 May 20;7:33. doi: 10.3389/fnint.2013.00033. eCollection 2013. PMID: 23730274; PMCID: PMC3657630.
Copy Download .nbib Format: NLM
Cognitive Functional Abilities in Parkinson's Disease: Agreement Between Patients and Informants.

Movement disorders clinical practice

Deck BL, Xie SX, Choi G, Rick J, Siderowf A, Rudovsky S, Chen-Plotkin A, Duda JE, Morley JF, Dahodwala N, Trojanowski JQ, Weintraub D.
PMID: 31392244
Mov Disord Clin Pract. 2019 May 17;6(6):440-445. doi: 10.1002/mdc3.12781. eCollection 2019 Jul.

BACKGROUND: The Penn Parkinson's Daily Activities Questionnaire-15 (PDAQ-15) assesses cognition-related instrumental activities of daily living (IADL) in Parkinson's disease (PD).OBJECTIVES: To assess the degree and predictors of disagreement between patients (PT) and knowledgeable informants (KI) on the PDAQ-15.METHODS: We...

Cite
Deck BL, Xie SX, Choi G, et al. Cognitive Functional Abilities in Parkinson's Disease: Agreement Between Patients and Informants. Mov Disord Clin Pract. 2019;6(6):440-445doi: 10.1002/mdc3.12781.
Deck, B. L., Xie, S. X., Choi, G., Rick, J., Siderowf, A., Rudovsky, S., Chen-Plotkin, A., Duda, J. E., Morley, J. F., Dahodwala, N., Trojanowski, J. Q., & Weintraub, D. (2019). Cognitive Functional Abilities in Parkinson's Disease: Agreement Between Patients and Informants. Movement disorders clinical practice, 6(6), 440-445. https://doi.org/10.1002/mdc3.12781
Deck, Benjamin L, et al. "Cognitive Functional Abilities in Parkinson's Disease: Agreement Between Patients and Informants." Movement disorders clinical practice vol. 6,6 (2019): 440-445. doi: https://doi.org/10.1002/mdc3.12781
Deck BL, Xie SX, Choi G, Rick J, Siderowf A, Rudovsky S, Chen-Plotkin A, Duda JE, Morley JF, Dahodwala N, Trojanowski JQ, Weintraub D. Cognitive Functional Abilities in Parkinson's Disease: Agreement Between Patients and Informants. Mov Disord Clin Pract. 2019 May 17;6(6):440-445. doi: 10.1002/mdc3.12781. eCollection 2019 Jul. PMID: 31392244; PMCID: PMC6660222.
Copy Download .nbib Format: NLM
The Vildagliptin Experience - 25 Years Since the Initiation of the Novartis Glucagon-like Peptide-1 Based Therapy Programme and 10 Years Since the First Vildagliptin Registration.

European endocrinology

Foley JE, Ahrén B.
PMID: 29632608
Eur Endocrinol. 2017 Aug;13(2):56-61. doi: 10.17925/EE.2017.13.02.56. Epub 2017 Aug 22.

The discovery of the incretin hormone glucagon like peptide-1 (GLP-1), and its usefulness in the treatment of type 2 diabetes mellitus (T2DM) followed by the finding that dipeptidyl peptidase-4 (DPP-4) inhibition prevents GLP-1 inactivation, led to the discovery of...

Cite
Foley JE, Ahrén B. The Vildagliptin Experience - 25 Years Since the Initiation of the Novartis Glucagon-like Peptide-1 Based Therapy Programme and 10 Years Since the First Vildagliptin Registration. Eur Endocrinol. 2017;13(2):56-61doi: 10.17925/EE.2017.13.02.56.
Foley, J. E., & Ahrén, B. (2017). The Vildagliptin Experience - 25 Years Since the Initiation of the Novartis Glucagon-like Peptide-1 Based Therapy Programme and 10 Years Since the First Vildagliptin Registration. European endocrinology, 13(2), 56-61. https://doi.org/10.17925/EE.2017.13.02.56
Foley, James E, and Ahrén, Bo. "The Vildagliptin Experience - 25 Years Since the Initiation of the Novartis Glucagon-like Peptide-1 Based Therapy Programme and 10 Years Since the First Vildagliptin Registration." European endocrinology vol. 13,2 (2017): 56-61. doi: https://doi.org/10.17925/EE.2017.13.02.56
Foley JE, Ahrén B. The Vildagliptin Experience - 25 Years Since the Initiation of the Novartis Glucagon-like Peptide-1 Based Therapy Programme and 10 Years Since the First Vildagliptin Registration. Eur Endocrinol. 2017 Aug;13(2):56-61. doi: 10.17925/EE.2017.13.02.56. Epub 2017 Aug 22. PMID: 29632608; PMCID: PMC5813465.
Copy Download .nbib Format: NLM
American Board of Orthodontics responds.

American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodontists, its constituent societies, and the American Board of Orthodontics

Dugoni SA, Chung CH, Tadlock LP, Barone N, Pangrazio-Kulbersh V, Sabott DG, Foley PF, Trulove TS, DeLeon E.
PMID: 28554435
Am J Orthod Dentofacial Orthop. 2017 Jun;151(6):1015-1016. doi: 10.1016/j.ajodo.2017.03.006.

No abstract available.

Cite
Dugoni SA, Chung CH, Tadlock LP, et al. American Board of Orthodontics responds. Am J Orthod Dentofacial Orthop. 2017;151(6):1015-1016doi: 10.1016/j.ajodo.2017.03.006.
Dugoni, S. A., Chung, C. H., Tadlock, L. P., Barone, N., Pangrazio-Kulbersh, V., Sabott, D. G., Foley, P. F., Trulove, T. S., & DeLeon, E. (2017). American Board of Orthodontics responds. American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodontists, its constituent societies, and the American Board of Orthodontics, 151(6), 1015-1016. https://doi.org/10.1016/j.ajodo.2017.03.006
Dugoni, Steven A, et al. "American Board of Orthodontics responds." American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodontists, its constituent societies, and the American Board of Orthodontics vol. 151,6 (2017): 1015-1016. doi: https://doi.org/10.1016/j.ajodo.2017.03.006
Dugoni SA, Chung CH, Tadlock LP, Barone N, Pangrazio-Kulbersh V, Sabott DG, Foley PF, Trulove TS, DeLeon E. American Board of Orthodontics responds. Am J Orthod Dentofacial Orthop. 2017 Jun;151(6):1015-1016. doi: 10.1016/j.ajodo.2017.03.006. PMID: 28554435.
Copy Download .nbib Format: NLM
Factors that may Account for Cardiovascular Risk Reduction with a Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin, in Young Patients with Type 2 Diabetes Mellitus.

Diabetes therapy : research, treatment and education of diabetes and related disorders

Evans M, Kozlovski P, Paldánius PM, Foley JE, Bhosekar V, Serban C, Avogaro A.
PMID: 29134608
Diabetes Ther. 2018 Feb;9(1):27-36. doi: 10.1007/s13300-017-0329-5. Epub 2017 Nov 13.

INTRODUCTION: In a meta-analysis, we observed a significant 37% relative risk reduction in prospectively adjudicated major adverse cardiac events [MACEs, comprising of non-fatal myocardial infarction, non-fatal stroke, cardiovascular (CV) death] with vildagliptin vs. comparators in younger (

Cite
Evans M, Kozlovski P, Paldánius PM, et al. Factors that may Account for Cardiovascular Risk Reduction with a Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin, in Young Patients with Type 2 Diabetes Mellitus. Diabetes Ther. 2017;9(1):27-36doi: 10.1007/s13300-017-0329-5.
Evans, M., Kozlovski, P., Paldánius, P. M., Foley, J. E., Bhosekar, V., Serban, C., & Avogaro, A. (2018). Factors that may Account for Cardiovascular Risk Reduction with a Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin, in Young Patients with Type 2 Diabetes Mellitus. Diabetes therapy : research, treatment and education of diabetes and related disorders, 9(1), 27-36. https://doi.org/10.1007/s13300-017-0329-5
Evans, Marc, et al. "Factors that may Account for Cardiovascular Risk Reduction with a Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin, in Young Patients with Type 2 Diabetes Mellitus." Diabetes therapy : research, treatment and education of diabetes and related disorders vol. 9,1 (2018): 27-36. doi: https://doi.org/10.1007/s13300-017-0329-5
Evans M, Kozlovski P, Paldánius PM, Foley JE, Bhosekar V, Serban C, Avogaro A. Factors that may Account for Cardiovascular Risk Reduction with a Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin, in Young Patients with Type 2 Diabetes Mellitus. Diabetes Ther. 2018 Feb;9(1):27-36. doi: 10.1007/s13300-017-0329-5. Epub 2017 Nov 13. PMID: 29134608; PMCID: PMC5801217.
Copy Download .nbib Format: NLM
Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase.

Oncotarget

Weisberg EL, Puissant A, Stone R, Sattler M, Buhrlage SJ, Yang J, Manley PW, Meng C, Buonopane M, Daley JF, Lazo S, Wright R, Weinstock DM, Christie AL, Stegmaier K, Griffin JD.
PMID: 28881711
Oncotarget. 2017 Jul 06;8(32):52026-52044. doi: 10.18632/oncotarget.19036. eCollection 2017 Aug 08.

Oncogenic FLT3 kinase is a clinically validated target in acute myeloid leukemia (AML), and both multi-targeted and selective FLT3 inhibitors have been developed. Spleen tyrosine kinase (SYK) has been shown to be activated and increased in FLT3-ITD-positive AML patients,...

Cite
Weisberg EL, Puissant A, Stone R, et al. Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase. Oncotarget. 2017;8(32):52026-52044doi: 10.18632/oncotarget.19036.
Weisberg, E. L., Puissant, A., Stone, R., Sattler, M., Buhrlage, S. J., Yang, J., Manley, P. W., Meng, C., Buonopane, M., Daley, J. F., Lazo, S., Wright, R., Weinstock, D. M., Christie, A. L., Stegmaier, K., & Griffin, J. D. (2017). Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase. Oncotarget, 8(32), 52026-52044. https://doi.org/10.18632/oncotarget.19036
Weisberg, Ellen L, et al. "Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase." Oncotarget vol. 8,32 (2017): 52026-52044. doi: https://doi.org/10.18632/oncotarget.19036
Weisberg EL, Puissant A, Stone R, Sattler M, Buhrlage SJ, Yang J, Manley PW, Meng C, Buonopane M, Daley JF, Lazo S, Wright R, Weinstock DM, Christie AL, Stegmaier K, Griffin JD. Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase. Oncotarget. 2017 Jul 06;8(32):52026-52044. doi: 10.18632/oncotarget.19036. eCollection 2017 Aug 08. PMID: 28881711; PMCID: PMC5581010.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 214 entries